Moran Wealth Management
STOK icon

Moran Wealth Management’s Stoke Therapeutics STOK Stock Holding History

Moran Wealth Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.15M Sell
44,296
-3,681
-8% -$111K 0.03% 369
2026
Q2 		$1.57M Buy
47,977
+7,425
+18% +$238K 0.04% 352
2026
Q1 		$1.32M Buy
+40,552
New +$1.33M 0.04% 340

Other funds holding STOK

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
Generali Investments Management
Generali Investments Management Ljubljana, Slovenia $517M AUM 27.81% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Moran Wealth Management's STOK Position: Q3 2026 in Review

Moran Wealth Management reduced its Stoke Therapeutics (STOK) stake by 7.7% in Q3 2026, selling an estimated $111K and leaving 44,296 shares worth $1.15M. The position accounts for 0.03% of the portfolio, ranked #369.

Moran Wealth Management first reported a position in STOK in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.57M in Q2 2026. 19 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • Moran Wealth Management held 44,296 shares of Stoke Therapeutics worth $1.15M as of Q3 2026.
  • Moran Wealth Management sold 3,681 Stoke Therapeutics shares in Q3 2026, an estimated $111K.
  • Stoke Therapeutics made up 0.03% of Moran Wealth Management's portfolio in Q3 2026, its #369 holding.
  • Moran Wealth Management first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Moran Wealth Management's Stoke Therapeutics position peaked at $1.57M in Q2 2026.
  • 19 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on Moran Wealth Management's 13F filing for Q3 2026, filed 22 Oct 2026.